NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for VIVS yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
successful commercialization led by new Chief Commercial Officer | The company raised capital recently and hired a new commercial chief. | Intact | no commercial progress or revenue acceleration reported in next year | Qualitative: Commercial partnership (Chemveda) and $5.0M milestone payment reported VivoSim partnered with Chemveda for AI drug testing and received a $5.0M milestone payment from Eli Lilly. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth thesis, not a proven compounder: current revenue is very low, the company is loss-making, and management execution has been volatile. The thesis is in a watch state, with recent financial performance below its industry cohort despite a recent improvement in the composite insight measure.
The valuation model indicates VIVS is cheap versus peers, while the expectations gap is close to neutral and the priced-in assessment is tagged justified. Confidence in that comparison is medium, and the evidence does not show a clear gap between market expectations and the company’s current operating record.
Near term, results remain uncertain: recent quarterly revenue was only $18,000 to $40,000, and the estimated chance of missing expectations is elevated for a small company in a high-miss-rate industry. Management expects over 500% revenue growth in fiscal 2027 from NAMs contract research services, but current evidence does not yet show that growth; capital raising has supported working capital, while Nasdaq compliance remains mixed.
The multi-year thesis hinges on whether product and market expansion turns the revenue goal into sustained, observable growth, and whether the company can maintain listing compliance without continued financing strain. Near term, guidance cuts or weaker employment data are risks, while continued strong results and guidance from Healthcare sector leaders could support sector momentum.
Over the next one to three years, VIVS remains a high-risk early-stage business with a cheap-versus-peers valuation but little evidence yet of durable revenue growth. The thesis depends on execution, financing, and continued listing compliance. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in VIVOSIM LABS INC's published investment case. The stated target is free cash flow yield >= 0%. |
| Broken |
| free cash flow yield remains below -2% beyond next year |
Valuation inputs unavailable A completed valuation measurement is required. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
achieve at least 20% revenue growth next year | Analysts expect 21% revenue growth next year. | Intact | YoY revenue growth falls below 15% next year | Revenue growth: -51.35% FY2027-Q1; GAAP. Published target: >=20% YoY revenue growth. Target period is not explicitly aligned with this observation. Aug 12, 2026-51.351351 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.